Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) fell 5.6% during trading on Tuesday . The company traded as low as $3.01 and last traded at $3.03, with a volume of 93,349 shares changing hands. The stock had previously closed at $3.21.

A number of research firms recently commented on DRNA. Cowen and Company reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Sunday, June 26th. Zacks Investment Research raised Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research note on Thursday, May 12th. Leerink Swann reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 10th. Chardan Capital decreased their price target on Dicerna Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating on the stock in a research note on Thursday, June 30th. Finally, Jefferies Group reissued a “buy” rating and issued a $19.00 price target on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 10th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $11.95.

The firm’s 50-day moving average is $3.27 and its 200-day moving average is $4.64. The stock’s market cap is $63.42 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.86) by $0.10. On average, equities research analysts anticipate that Dicerna Pharmaceuticals Inc. will post ($3.34) earnings per share for the current fiscal year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.